1.
Journal of Clinical Hepatology
;
(12): 798-801, 2016.
Artigo
em Chinês
| WPRIM
| ID: wpr-778618
RESUMO
In recent years, new changes have occurred in the treatment of chronic hepatitis C. Direct-acting antiviral agents have shown powerful efficacy in the treatment of active hepatitis C, and even refractory hepatitis C shows a high continuous virologic response. Among these direct-acting antiviral agents, sofosbuvir (SOF) has the advantages of short course of antiviral treatment and high response rate, and some patients with certain hepatitis C genotypes have no need to receive interferon therapy. This article introduces the mechanism of action, current status of clinical application, and major adverse effects of SOF, and points out its promising future in patients with refractory hepatitis C.